An ongoing clinical trial (October, 2015) has compared the overall survival of women with advanced (Stage III) or metastatic (Stage IV) HER2-negative breast cancer who received treatment with capecitabine in combination with ruxolitinib versus those who received treatment solely with capecitabine (https://clinicaltrials.gov) [4]. Here, ERBB2 is linked to breast cancer.